Certificati di investimento - Cap. 4

Stato
Chiusa ad ulteriori risposte.
Comunque chi desiderava volatilità direi che da Madame Lagarde in poi può anche considerarsi soddisfatto...
 
Buy DE000VP7K7K3... buon PM di Biogen...

  • The FDA has extended the review period by three months for Biogen and Eisai's Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease.
  • The updated PDUFA action date is June 7, 2021.
  • Biogen submitted a response to an information request by the FDA, including additional analyses and clinical data, which was considered as a major amendment that will require additional time for review.
  • Biogen licensed aducanumab from Neurimmune and since October 2017, Biogen and Eisai have collaborated on the development of aducanumab globally.
  • BIIB shares up 10% premarket.
 
Stato
Chiusa ad ulteriori risposte.

Users who are viewing this thread

Back
Alto